What is the CVSS score of CVE-2021-27288?

CVE-2021-27288 has a CVSS 3.1 base score of 6.1 (Medium). CVSS vector: CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:C/C:L/I:L/A:N. EPSS exploitation probability: 0.9%.

Is there a public PoC exploit available for CVE-2021-27288?

Yes, a public proof-of-concept exploit is available for CVE-2021-27288. Prioritise patching immediately. EPSS: 0.9%.

X2Crm CVE-2021-27288

MEDIUM

Cross-site Scripting (XSS) (CWE-79)

2021-04-14 cve@mitre.org

XSS X2Crm

6.1

CVSS 3.1 · NVD

Severity by source

NVD PRIMARY

6.1 MEDIUM

AV:N/AC:L/PR:N/UI:R/S:C/C:L/I:L/A:N

Primary rating from NVD · only source for this CVE.

CVSS VectorNVD

CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:C/C:L/I:L/A:N

Attack Vector

Network

Attack Complexity

Low

Privileges Required

None

User Interaction

Required

Scope

Changed

Confidentiality

Low

Integrity

Low

Availability

None

Lifecycle Timeline

CVE Published

Apr 14, 2021 - 14:15 nvd

MEDIUM 6.1

DescriptionNVD

AnalysisAI

Cross Site Scripting (XSS) in X2Engine X2CRM v7.1 allows remote attackers to obtain sensitive information by injecting arbitrary web script or HTML via the "Comment" field in "/profile/activity" page. Rated medium severity (CVSS 6.1), this vulnerability is remotely exploitable, no authentication required, low attack complexity. Public exploit code available and no vendor patch available.

Technical ContextAI

This vulnerability is classified as Cross-Site Scripting (XSS) (CWE-79), which allows attackers to inject malicious scripts into web pages viewed by other users. Cross Site Scripting (XSS) in X2Engine X2CRM v7.1 allows remote attackers to obtain sensitive information by injecting arbitrary web script or HTML via the "Comment" field in "/profile/activity" page. Affected products include: X2Engine X2Crm.

RemediationAI

No vendor patch is available at time of analysis. Monitor vendor advisories for updates. Sanitize all user input, use Content-Security-Policy headers, encode output contextually (HTML, JS, URL). Use frameworks with built-in XSS protection.